Related Experiment Video

Updated: Apr 29, 2026

Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique
09:37

Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique

Published on: September 23, 2022

1.8K

Palivizumab use in Japanese infants and children with immunocompromised conditions

Masaaki Mori1, Masafumi Onodera, Akira Morimoto

  • 1From the *Department of Pediatrics, Yokohama City University Medical Center, Yokohama; †Department of Human Genetics, National Center for Child Health and Development, Tokyo; ‡Department of Pediatrics, Jichi Medical University School of Medicine, Shimotsuke; §Department of Hematology and Oncology, Hyogo Prefectural Kobe Children's Hospital, Kobe; ¶Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University Graduate School of Medical and Dental Sciences, Tokyo; ‖Virology; **Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, IL; and ††Department of Pediatrics, Toho University Medical Center Omori Hospital, Tokyo, Japan.

The Pediatric Infectious Disease Journal
|May 17, 2014
PubMed

Insights

Palivizumab effectively prevented respiratory syncytial virus hospitalizations in immunocompromised Japanese children. High palivizumab doses were well-tolerated, with no drug-related serious adverse events observed.

Area of Science:

  • Pediatrics
  • Immunology
  • Infectious Diseases

Background:

  • Respiratory syncytial virus (RSV) poses a significant threat to immunocompromised children.
  • Palivizumab is an antibody used for RSV prophylaxis.

Purpose of the Study:

  • To evaluate the efficacy and safety of palivizumab in immunocompromised Japanese children.
  • To assess palivizumab trough concentrations in this population.

Main Methods:

  • A cohort of 28 immunocompromised Japanese children received palivizumab.
  • RSV-associated hospitalizations and adverse events were monitored.
  • Palivizumab trough concentrations were measured after the 1st and 4th doses.

Main Results:

  • 96% of children received at least 4 doses of palivizumab.
  • No RSV-associated hospitalizations were reported.
  • Mean palivizumab trough concentrations were 59.0 μg/mL (after 1st dose) and 91.8 μg/mL (after 4th dose).
  • 25% of children experienced serious adverse events, none linked to palivizumab.

Conclusions:

  • Palivizumab prophylaxis was effective in preventing RSV hospitalizations in this cohort.
  • Palivizumab demonstrated a favorable safety profile in immunocompromised Japanese children.
  • Achieved palivizumab concentrations suggest adequate therapeutic levels.

More Related Videos

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

14.5K
Standardization of Transfer across Labs between Flow Cytometers for Detection of Lymphocytes in Japanese Encephalitis Vaccinated Children06:22

Standardization of Transfer across Labs between Flow Cytometers for Detection of Lymphocytes in Japanese Encephalitis Vaccinated Children

Published on: February 10, 2023

1.3K

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
3.6K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.2K
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
4.2K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
753